

FILE 'HOME' ENTERED AT 21:40:05 ON 26 SEP 2011

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.23	0.23

FILE 'REGISTRY' ENTERED AT 21:40:12 ON 26 SEP 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2011 HIGHEST RN 1333308-28-3
DICTIONARY FILE UPDATES: 25 SEP 2011 HIGHEST RN 1333308-28-3

CAS Information Use Policies apply and are available at: www.cas.org/casinfo

<http://www.cas.org/legal/infopolicy.html>


TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stnqgen/stndoc/properties.html>

=>
Uploading C:\Users\afierro\Documents\STN Express 8.4\Queries\10573176_claim7.str



chain nodes :

10 17 18 19 20 21 22 30 32

ring nodes :

Ring heads : 1 2 3 4 5 6 7 8 9 11 12 13

chain bonds :

chain bonds

Spring 1

1-2

15-16

1-9 6-7 7-8 8-9 8-10 10-11 17-18 19-20 21-22
exact bonds :
10-32
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16

G1:[@1],[@2],[@3]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:Atom 19:CLASS
20:Atom 21:CLASS
22:Atom 30:CLASS 31:CLASS 32:CLASS
Generic attributes :
18:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System : Monocyclic
20:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System : Monocyclic
22:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System : Monocyclic


Element Count :
Node 18: Limited
C,Exact,5
N,Exact,1

Node 20: Limited
C,Exact,5
N,Exact,1

Node 22: Limited
C,Exact,5
N,Exact,1

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1:[@1],[@2],[@3]

Structure attributes must be viewed using STN Express query preparation.

```
=> s ll sss sam
SAMPLE SEARCH INITIATED 21:40:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      293 TO ITERATE


100.0% PROCESSED      293 ITERATIONS          1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:   4833 TO   6887
PROJECTED ANSWERS:       1 TO     80

L2      1 SEA SSS SAM L1

=> d scan
```

```
L2      1 ANSWERS  REGISTRY COPYRIGHT 2011 ACS on STN
IN  2-Benzoxazolamine, N-[4-[(2'-fluoro[3,4'-bipyridin]-2-yl)oxy]phenyl]-
MF  C23 H15 F N4 O2
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> s 11 sss full
FULL SEARCH INITIATED 21:40:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      5740 TO ITERATE
```

```
100.0% PROCESSED      5740 ITERATIONS          36 ANSWERS
SEARCH TIME: 00.00.01
```

```
L3      36 SEA SSS FUL L1
```

```
=> file capl
COST IN U.S. DOLLARS           SINCE FILE      TOTAL
                               ENTRY        SESSION
FULL ESTIMATED COST          196.86       197.09
```

```
FILE 'CAPLUS' ENTERED AT 21:40:42 ON 26 SEP 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Sep 2011 VOL 155 ISS 14
FILE LAST UPDATED: 25 Sep 2011 (20110925/ED)
REVISED CLASS FIELDS ('NCL') LAST RELOADED: Aug 2011
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2011

Cplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2011.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 13
L4      6 L3
=> d 1-6 ibib hitstr
```

```
L4  ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2011:38889  CAPLUS <<LOGINID::20110926>>
DOCUMENT NUMBER: 154:109614
TITLE: Preparation of multi-cyclic compounds useful in
treatment of oncol. diseases related to kinase
activity
INVENTOR(S): Cee, Victor J.; Deak, Holly L.; Geuns-Meyer, Stephanie
D.; Hodous, Brian L.; Nguyen, Hanh Nho; Olivier,
Philip R.; Patel, Vinod F.; Romero, Karina
PATENT ASSIGNEE(S): Amgen Inc., USA
```

SOURCE:

U.S., 41pp.; Chemical Indexing Equivalent to
147:344090 (WO)
CODEN: USXXAM

DOCUMENT TYPE:

Patent
English

LANGUAGE:

2

FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7868177	B2	20110111	US 2007-709994	20070221
US 20070213325	A1	20070913		
AU 2007221294	A1	20070907	AU 2007-221294	20070222
CA 2643177	A1	20070907	CA 2007-2643177	20070222
CA 2643177	C	20110614		
WO 2007100646	A1	20070907	WO 2007-US4700	20070222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1994030	A1	20081126	EP 2007-751460	20070222
EP 1994030	B1	20100825		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
AT 478861	T	20100915	AT 2007-751460	20070222
ES 2347489	T3	20101029	ES 2007-751460	20070222
PRIORITY APPLN. INFO.:			US 2006-776507P	P 20060224
			US 2007-709994	A 20070221
			WO 2007-US4700	W 20070222


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

IT 948562-79-6P 948562-90-1P 948563-30-2P
948563-32-4P 948563-34-6P 948563-36-8P
948563-50-6P 948563-53-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of novel multicyclic compds. useful in treatment of oncol.
diseases related to kinase activity)


RN 948562-79-6 CAPLUS
CN 2-Benzoxazolamine, N-[3-methyl-4-[(3-(4-pyrimidinyl)-2-
pyridinyl)oxy]phenyl]- (CA INDEX NAME)




RN 948562-90-1 CAPLUS
CN 2-Benzoxazolamine, N-[4-[(3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl)oxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 948563-30-2 CAPLUS
CN 2-Benzoxazolamine, 5,7-dimethyl-N-[3-methyl-4-[(3-(4-pyrimidinyl)-2-pyridinyl)oxy]phenyl]- (CA INDEX NAME)




RN 948563-32-4 CAPLUS
CN 2-Benzoxazolamine, 6-methyl-N-[3-methyl-4-[(3-(4-pyrimidinyl)-2-pyridinyl)oxy]phenyl]- (CA INDEX NAME)




RN 948563-34-6 CAPLUS
CN 2-Benzoxazolamine, 5-methyl-N-[3-methyl-4-[(3-(4-pyrimidinyl)-2-

pyridinyl]oxy]phenyl]- (CA INDEX NAME)




RN 948563-36-8 CAPLUS

CN 2-Benzoxazolamine, 4-methyl-N-[3-methyl-4-[(3-(4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)




RN 948563-50-6 CAPLUS

CN 2-Benzoxazolamine, N-[4-[(3-[(2-(methylamino)-4-pyrimidinyl)-2-pyridinyl]oxy)phenyl]- (CA INDEX NAME)



RN 948563-53-9 CAPLUS

CN 2-Benzoxazolamine, N-[3-methyl-4-[(3-[(2-(methylamino)-4-pyrimidinyl)-2-pyridinyl]oxy)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2010:625658 CAPLUS <<LOGINID::20110926>>
DOCUMENT NUMBER: 152:592058
TITLE: Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
INVENTOR(S): Allen, Jennifer R.; Biswas, Kaustav; Chavez, Frank, Jr.; Chen, Ning; Demorin, Frenel Fils; Falsey, James R.; Frohn, Mike; Harrington, Paul; Horne, Dan; Hu, Essa; Kaller, Matthew R.; Kunz, Roxanne; Monenschein, Holger; Nguyen, Tom; Pickrell, Alex; Reichelt, Andreas; Rumfelt, Shannon; Rzasa, Rob; Sham, Kelvin; Yao, Guomin
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 396pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010057126	A1	20100520	WO 2009-US64643	20091116
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, ZA, ZM, ZW	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AR 74343	A1	20101012	AR 2009-104404	20091113
AU 2009313773	A1	20100520	AU 2009-313773	20091116
CA 2742833	A1	20100520	CA 2009-2742833	20091116
US 20100125062	A1	20100520	US 2009-619573	20091116
KR 2011086603	A	20110728	KR 2011-7013477	20091116
EP 2364306	A1	20101014	EP 2009-752706	20091116
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, AL, BA, RS				
PRIORITY APPLN. INFO.:			US 2008-114595P	P 20081114
			US 2009-166215P	P 20090402
			WO 2009-US64643	W 20091116

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 152:592058; MARPAT 152:592058


IT 1227176-68-2P 1227177-95-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyridine and pyrimidine derivs. as phosphodiesterase 10 inhibitors useful in treatment of diseases)


RN 1227176-68-2 CAPLUS

CN 2-Benzoxazolamine, N-[4-[(3-bromo-2-pyridinyl)oxy]phenyl]- (CA INDEX


NAME)




RN 1227177-95-8 CAPLUS
CN 2-Benzoxazolamine, N-[4-[(3,4-dihydro-2H-pyran-2-yl)-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)




IT 1227173-64-9P 1227174-18-6P 1227174-64-2P
1227175-29-2P 1227175-30-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridine and pyrimidine derivs. as phosphodiesterase 10 inhibitors useful in treatment of diseases)
RN 1227173-64-9 CAPLUS
CN 2-Benzoxazolamine, N-[4-[(3-methyl-2-pyridinyl)oxy]phenyl]- (CA INDEX NAME)




RN 1227174-18-6 CAPLUS
CN 2-Benzoxazolamine, N-[4-[(3-cyclopropyl-2-pyridinyl)oxy]phenyl]- (CA INDEX NAME)




RN 1227174-64-2 CAPLUS
CN 2-Benzoxazolamine, N-[4-[(3-(tetrahydro-2H-pyran-4-yl)-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)



RN 1227175-29-2 CAPLUS
CN 2-Benzoxazolamine, N-[4-[(2'-fluoro[3,4'-bipyridin]-2-yl)oxy]phenyl]- (CA INDEX NAME)




RN 1227175-30-5 CAPLUS
CN 2-Benzoxazolamine, N-[4-[(2'-methoxy[3,3'-bipyridin]-2-yl)oxy]phenyl]- (CA INDEX NAME)




IT 1227177-95-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridine and pyrimidine derivs. as phosphodiesterase 10

inhibitors useful in treatment of diseases)
RN 1227177-95-8 CAPLUS
CN 2-Benzoxazolamine, N-[4-[(3-(3,4-dihydro-2H-pyran-2-yl)-2-pyridinyl)oxy]phenyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2010:587107 CAPLUS <>LOGINID::20110926>>
DOCUMENT NUMBER: 153:29224
TITLE: Analysis of Kinase Inhibitor Selectivity using a
Thermodynamics-Based Partition Index
AUTHOR(S): Cheng, Alan C.; Eksterowicz, John; Geuns-Meyer,
Stephanie; Sun, Yaxiong
CORPORATE SOURCE: Molecular Structure Department, Amgen Inc., Cambridge,
MA, 02142, USA
SOURCE: Journal of Medicinal Chemistry (2010), 53(11),
4502-4510
PUBLISHER: CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: American Chemical Society
LANGUAGE: Journal
English
IT 948562-90-1
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological
study)
(anal. of kinase inhibitor selectivity using a thermodn.-based
partition index)
RN 948562-90-1 CAPLUS
CN 2-Benzoxazolamine, N-[4-[(3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl)oxy]-1-naphthalenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
 (4 CITINGS)
 REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2009:6204 CAPLUS <<LOGINID::20110926>>
 DOCUMENT NUMBER: 150:274896
 TITLE: Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase
 AUTHOR(S): Cee, Victor J.; Cheng, Alan C.; Romero, Karina; Bellon, Steve; Mohr, Christopher; Whittington, Douglas A.; Bak, Annette; Bready, James; Caenepeel, Sean; Coxon, Angela; Deak, Holly L.; Fretland, Jenne; Gu, Yan; Hodous, Brian L.; Huang, Xin; Kim, Joseph L.; Lin, Jasmine; Long, Alexander M.; Nguyen, Hanh; Olivieri, Philip R.; Patel, Vinod F.; Wang, Ling; Zhou, Yihong; Hughes, Paul; Geuns-Meyer, Stephanie
 CORPORATE SOURCE: Department of Medicinal Chemistry, Amgen Inc., Cambridge, MA, 02139, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2009), 19(2), 424-427
 PUBLISHER: CODEN: BMCL8; ISSN: 0960-894X
 DOCUMENT TYPE: Elsevier Ltd.
 LANGUAGE: Journal
 OTHER SOURCE(S): English
 IT 948562-90-1 CASREACT 150:274896
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pyridyl-pyrimidine benzimidazole derivs. as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase)
 RN 948562-90-1 CAPLUS
 CN 2-Benzoxazolamine, N-[4-[(3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl)oxy]l-1-naphthalenyl - (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
 (5 CITINGS)
 REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2007:998153 CAPLUS <<LOGINID::20110926>>
 DOCUMENT NUMBER: 147:344090
 TITLE: Preparation of multi-cyclic compounds useful in treatment of oncol. diseases related to kinase activity
 INVENTOR(S): Cee, Victor J.; Deak, Holly L.; Geuns-Meyer, Stephanie D.; Hodous, Brian L.; Nguyen, Hanh Nho; Olivieri, Philip R.; Patel, Vinod F.; Romero, Karina
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 104pp.; Chemical Indexing Equivalent to 154:109614 (US)
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007100646	A1	20070907	WO 2007-US4700	20070222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 7868177	B2	20110111	US 2007-709994	20070221
US 20070213325	A1	20070913		
AU 2007221294	A1	20070907	AU 2007-221294	20070222
CA 2643177	A1	20070907	CA 2007-2643177	20070222

CA 2643177	C	20110614		
EP 1994030	A1	20081126	EP 2007-751460	20070222
EP 1994030	B1	20100825		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
AT 478861	T	20100915	AT 2007-751460	20070222
PRIORITY APPLN. INFO.:				
US 2006-776507P P 20060224				
US 2007-709994 A 20070221				
WO 2007-US4700 W 20070222				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 147:344090; MARPAT 147:344090


IT 948562-79-6P 948562-90-1P 948563-30-2P
948563-32-4P 948563-34-6P 948563-36-8P
948563-50-6P 948563-53-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel multicyclic compds. useful in treatment of oncol.
diseases related to kinase activity)


RN 948562-79-6 CAPLUS

CN 2-Benzoxazolamine, N-[3-methyl-4-[(3-(4-pyrimidinyl)-2-pyridinyl)oxy]phenyl]- (CA INDEX NAME)




RN 948562-90-1 CAPLUS

CN 2-Benzoxazolamine, N-[4-[(3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl)oxy]-1-naphthalenyl]- (CA INDEX NAME)




RN 948563-30-2 CAPLUS

CN 2-Benzoxazolamine, 5,7-dimethyl-N-[3-methyl-4-[[3-(4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)




RN 948563-32-4 CAPLUS

CN 2-Benzoxazolamine, 6-methyl-N-[3-methyl-4-[[3-(4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)




RN 948563-34-6 CAPLUS

CN 2-Benzoxazolamine, 5-methyl-N-[3-methyl-4-[[3-(4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)




RN 948563-36-8 CAPLUS


CN 2-Benzoxazolamine, 4-methyl-N-[3-methyl-4-[[3-(4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)



RN 948563-50-6 CAPLUS
CN 2-Benzoxazolamine, N-[4-[(3-[(2-(methylamino)-4-pyrimidinyl]2-pyridinyl)oxy]phenyl]- (CA INDEX NAME)



RN 948563-53-9 CAPLUS
CN 2-Benzoxazolamine, N-[3-methyl-4-[(3-[(2-(methylamino)-4-pyrimidinyl]2-pyridinyl)oxy]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2005:345863 CAPLUS <>
DOCUMENT NUMBER: 142:411345
TITLE: Preparation of 1,3-benzoxazoles as TIE-2 kinase
inhibitors
INVENTOR(S): Staehle, Wolfgang; Jonczyk, Alfred; Rautenberg,
Wilfried
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: Ger. Offen., 36 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10344223	A1	20050421	DE 2003-10344223	20030924
AU 2004281879	A1	20050428	AU 2004-281879	20040901
AU 2004281879	B2	20110407		
CA 2539767	A1	20050428	CA 2004-2539767	20040901
WO 2005037829	A1	20050428	WO 2004-EP5743	20040901
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, CZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1664039	A1	20060607	EP 2004-764704	20040901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007506687	T	20070322	JP 2006-527292	20040901
US 20060281762	A1	20061214	US 2006-573176	20060323
PRIORITY APPLN. INFO.:			DE 2003-10344223	A 20030924
			WO 2004-EP5743	W 20040901

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 142:411345


IT 850258-31-0P 850258-34-3P 850258-37-6P
 850258-39-8P 850258-41-2P 850258-44-5P
 850258-47-8P 850258-50-3P 850258-53-6P
 850258-56-9P 850258-58-1P 850258-61-6P
 850258-66-1P 850258-68-3P 850258-70-7P
 850258-72-9P 850258-74-1P 850258-82-1P
 850258-84-3P 850260-56-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


(preparation of benzoxazoles as TIE-2 kinase inhibitors)

RN 850258-31-0 CAPLUS


CN 2-Benzoxazolamine, N-[4-(4-pyridinyl)phenyl]- (CA INDEX NAME)




RN 850258-34-3 CAPLUS
 CN 2-Benzoxazolamine, N-[4-(4-pyridinyl)phenyl]- (CA INDEX NAME)




RN 850258-37-6 CAPLUS
CN 1,4-Benzenediamine, N1-2-benzoxazolyl-N4-4-pyridinyl- (CA INDEX NAME)




RN 850258-39-8 CAPLUS
CN 5-Benzoxazolecarboxylic acid, 2-[(4-(4-pyridinylthio)phenyl)amino]- (CA INDEX NAME)




RN 850258-41-2 CAPLUS
CN 6-Benzoxazolecarboxylic acid, 2-[(4-(4-pyridinylthio)phenyl)amino]- (CA INDEX NAME)




RN 850258-44-5 CAPLUS
CN 6-Benzoxazolecarboxylic acid, 2-[(4-(4-pyridinylthio)phenyl)amino]- (CA INDEX NAME)




RN 850258-47-8 CAPLUS
CN 6-Benzoxazolecarboxylic acid, 2-[4-(4-pyridinylamino)phenyl]amino-,
methyl ester (CA INDEX NAME)




RN 850258-50-3 CAPLUS
CN 2-Benzoxazolamine, 5-nitro-N-[4-(4-pyridinylthio)phenyl]- (CA INDEX NAME)




RN 850258-53-6 CAPLUS
CN 2-Benzoxazolamine, 5-nitro-N-[4-(4-pyridinylloxy)phenyl]- (CA INDEX NAME)




RN 850258-56-9 CAPLUS
CN 1,4-Benzenediamine, N1-(5-nitro-2-benzoxazolyl)-N4-4-pyridinyl- (CA INDEX NAME)




RN 850258-58-1 CAPLUS
CN 2-Benzoxazolamine, 6-nitro-N-[4-(4-pyridinyloxy)phenyl]- (CA INDEX NAME)




RN 850258-61-6 CAPLUS
CN 2-Benzoxazolamine, 6-nitro-N-[4-(4-pyridinylthio)phenyl]- (CA INDEX NAME)




RN 850258-66-1 CAPLUS
CN 2-Benzoxazolamine, 5-chloro-7-nitro-N-[4-(4-pyridinyloxy)phenyl]- (CA INDEX NAME)




RN 850258-68-3 CAPLUS
CN 2-Benzoxazolamine, 5-chloro-7-nitro-N-[4-(4-pyridinylthio)phenyl]- (CA INDEX NAME)




RN 850258-70-7 CAPLUS
 CN 1,4-Benzenediamine, N1-(5-chloro-7-nitro-2-benzoxazolyl)-N4-4-pyridinyl-
 (CA INDEX NAME)




RN 850258-72-9 CAPLUS
 CN 2-Benzoxazolamine, 7-bromo-N-[4-(4-pyridinylthio)phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)




RN 850258-74-1 CAPLUS
 CN 2-Benzoxazolamine, 7-bromo-N-[4-(4-pyridinylthio)phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)




RN 850258-82-1 CAPLUS
 CN 2-Pyridinecarboxamide, 4-[4-[[7-bromo-5-(trifluoromethyl)-2-benzoxazolyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 850258-84-3 CAPLUS
 CN 2-Pyridinecarboxamide, 4-[(4-[(7-bromo-5-(trifluoromethyl)-2-benzoxazolyl)amino]phenyl)thio]-N-methyl- (CA INDEX NAME)



RN 850260-56-9 CAPLUS
 CN 1,4-Benzenediamine, N1-(6-nitro-2-benzoxazolyl)-N4-4-pyridinyl- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
 (5 CITINGS)

=> log
 ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
 LOGOFF? (Y)/N/HOLD:y

(FILE 'HOME' ENTERED AT 21:40:05 ON 26 SEP 2011)

FILE 'REGISTRY' ENTERED AT 21:40:12 ON 26 SEP 2011
 L1 STRUCTURE uploaded
 D
 L2 1 SEA FILE=REGISTRY SSS SAM L1
 D SCAN
 L3 36 SEA FILE=REGISTRY SSS FUL L1

FILE 'CAPLUS' ENTERED AT 21:40:42 ON 26 SEP 2011
 L4 6 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L3
 D 1-6 IBIB HITSTR